Atrion (NASDAQ:ATRI) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Atrion (NASDAQ:ATRI) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the medical instruments supplier’s stock.

Atrion Price Performance

Shares of ATRI opened at $457.65 on Thursday. Atrion has a 52-week low of $274.98 and a 52-week high of $575.88. The firm’s fifty day moving average is $456.19 and its two-hundred day moving average is $415.06. The stock has a market cap of $805.46 million, a PE ratio of 43.01 and a beta of 0.68.

Atrion (NASDAQ:ATRI) last announced its quarterly earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share for the quarter. The firm had revenue of $47.33 million for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%.

Atrion Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Friday, June 14th were given a dividend of $2.20 per share. The ex-dividend date of this dividend was Friday, June 14th. This represents a $8.80 annualized dividend and a dividend yield of 1.92%. Atrion’s payout ratio is 82.71%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ATRI. Penn Mutual Asset Management LLC purchased a new stake in Atrion in the 4th quarter valued at about $1,949,000. Public Employees Retirement System of Ohio purchased a new stake in Atrion in the 1st quarter valued at about $2,299,000. Citizens Financial Group Inc. RI purchased a new stake in Atrion in the 4th quarter valued at about $1,114,000. Boston Trust Walden Corp raised its holdings in Atrion by 4.8% in the 4th quarter. Boston Trust Walden Corp now owns 35,091 shares of the medical instruments supplier’s stock valued at $13,292,000 after buying an additional 1,609 shares during the period. Finally, State Board of Administration of Florida Retirement System purchased a new stake in Atrion in the 1st quarter valued at about $421,000. Institutional investors and hedge funds own 66.19% of the company’s stock.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.